@mrscaitlinkirrane's hormone therapy claims, fact-checked

What did @mrscaitlinkirrane actually say?

She started HRT one month ago, prescribed by a women's health specialist, to manage what she and her doctor suspect is PMDD, possibly compounded by early perimenopause. Her regimen is an estrogen spray applied daily to her arms, plus a progesterone pill taken for 25 days with a 3-day break, rather than the more typical 14-days-on, 14-days-off cycle. She attributes the unusual dosing schedule to being "so sensitive to hormones." She's clear that she doesn't have a formal PMDD diagnosis, and her doctor told her she likely won't reach full menopause for another decade or more.

She also describes six months of trying lifestyle interventions first: stopping alcohol, taking supplements, maintaining physical activity. None of it was enough. This detail matters because it shows she didn't jump straight to hormones, which is worth noting.

Does the science back this up?

Mostly, yes. The evidence for transdermal estrogen in managing PMDD and perimenopausal symptoms is reasonably solid, though not without caveats. A continuous combined or long-cycle progesterone approach like hers has real clinical backing.

PMDD affects an estimated 3-8% of women of reproductive age, and the underlying mechanism involves abnormal sensitivity to normal fluctuations in progesterone metabolites, particularly allopregnanolone, rather than absolute hormone deficiency (Bixo et al., 2017, American Journal of Obstetrics and Gynecology). This actually supports her description of feeling every "slight change."

Transdermal estradiol is used off-label to suppress ovarian cyclicity in PMDD, and there is clinical trial evidence for this approach. Studd and Panay (2004, Menopause International) showed that estradiol patches reduced PMDD symptoms significantly when combined with cyclical progestogens. The spray formulation she describes delivers estradiol similarly to patches. Using micronized progesterone for fewer days to reduce the progestogenic symptom burden is also an established clinical strategy for hormone-sensitive patients.

What did they get wrong (or right)?

She used the phrase "primary menopause" repeatedly when she almost certainly means "perimenopause." This is a minor language slip, not a dangerous one, but it could confuse viewers. Primary ovarian insufficiency is a distinct condition affecting women under 40. She doesn't appear to have that.

She's right that PMDD is genuinely hard to diagnose. The DSM-5 criteria require prospective symptom tracking across at least two menstrual cycles, and many clinicians skip this step. Her doctor's pragmatic approach of treating the symptom picture rather than waiting for a formal diagnosis reflects real-world clinical practice, and it's not wrong. The RCOG and IAPMD both acknowledge that diagnostic delays are common and costly.

Her claim that lifestyle changes including stopping alcohol, taking supplements, and exercising consistently for six months didn't resolve her symptoms is entirely plausible and consistent with research. Lifestyle interventions are recommended as first-line for mild-to-moderate PMDD but have limited evidence for severe presentations (ACOG Practice Bulletin, 2023).

One thing she gets genuinely right: she went to a specialist rather than trying to self-diagnose or self-treat. That is the correct move, and it's worth saying plainly.

What should you actually know?

If you're watching this and wondering whether HRT is appropriate for your PMDD or perimenopausal symptoms, the honest answer is: it depends, and you need a proper clinical assessment, not an Instagram video, including this one.

HRT is not a universal fix for PMDD. For some people, adding exogenous progesterone worsens symptoms because of that same allopregnanolone sensitivity. The extended progesterone dosing schedule she describes (25 days on, 3 days off) is specifically designed to reduce cyclical progestogenic side effects, which suggests her doctor is thinking carefully about this. That's not standard; it's individualized.

Transdermal estrogen is generally considered safer than oral estrogen from a cardiovascular and thrombotic risk standpoint, particularly in women under 60 (Canonico et al., 2007, Circulation). So the spray-based delivery method she's using is clinically sensible, not a quirky choice.

If you suspect PMDD, track your symptoms prospectively using a validated tool like the DRSP (Daily Record of Severity of Problems) before seeing a doctor. It makes the consultation considerably more productive.